Companies › Pasithea Therapeutics
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PAS-004 MEK 1/2 inhibitor | MAP2K1, MAP2K2 | Phase 1 | RAS Mutation; NF1 Mutation | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06299839 | PAS-004 | Phase 1 | RAS Mutation | Oncology | Sep 2027 |
| NCT06961565 | PAS-004 | Phase 1 | NF1 Mutation | Oncology | Feb 2028 |
Cash of $46m on 2026-06-30; operating cash outflow about $19m a year; runway about 28 months at that burn, to Nov 2028
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.